Dana-farber-cancer Institute Inc.

Harvard College

William N Haining

Robert Manguso

Arlene Helen Sharpe

Jernej Godec

Matthew Meyerson

Jeffrey Ishizuka

Hugh Gannon

Adrienne Long

Natalie Collins

Arlene H Sharpe

The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that modulates one or more biomarkers, such as inhibits one or more biomarkers listed in Table 1 and/or increases one or more biomarkers listed in Table 4, in combination with an immunotherapy.

Modulating biomarkers such as SPP to increase tumor immunity and improve the efficacy of cancer immunotherapy

The present invention relates, in part, to methods of treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an agent that inhibits or promotes the copy number, the expression level, and/or the activity of one or more biomarkers listed in Table 1 or a fragment thereof. Also provided herein are methods of detecting ADAR1 or ISG15 dependency in a high proliferation cell (e.g., a cancer cell). Also provided are methods of detected increased interferon signaling pathway activity in a high proliferation cell (e.g., a cancer cell). Included herein are methods of treating cancer with inhibitors of ADAR1 or ISG15. Methods of screening for such inhibitors are also provided herein. Methods of identifying the likelihood of a cancer to be responsive to an ADAR1 inhibitor are also provided.

Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon

The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits one or more biomarkers listed in Table 1 in combination with an immunotherapy.

Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy

The invention provides in vivo methods for identifying cancer-associated immunotherapy targets.

In vivo methods for identifying cancer-associated immunotherapy targets

The present invention is based on the identification, of compositions and methods for the identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators.

Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators

The invention provides methods and compositions for perturbing gene expression in hematopoietic cell lineages in vivo.

Growing community of inventors

Newton, MA, United States of America

William N Haining